Bifidobacterium animalis subsp. lactis BB-12 for Common Cold
Verdict: Published with Warning
Across 6 PubMed studies, the evidence for Bifidobacterium animalis subsp. lactis BB-12 in Common Cold grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
BB-12 does not have strain-specific meta-analytic support for cold prevention. The Cochrane review (PMID 36001877) pools multiple probiotic strains and cannot attribute benefit to BB-12 alone. Hojsak 2016 (PMID 26031908, n=210) found no infection prevention with BB-12.
A separate meta-analysis (PMID 29752587) confirms the BB-12 subgroup showed null effects for respiratory infection outcomes. Marketing often extrapolates genus-level probiotic evidence to specific strains without justification.
Tier C with warning reflects this weak, non-attributable evidence base. Probiotics may help some populations, but BB-12 specifically lacks replicated cold-prevention benefit.
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.46
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
58%
Conflicting evidence
Evidence level
E3
Cochrane 36001877 is multi-strain; Hojsak 2016 (26031908) shows BB-12 subgroup null
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.457
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Probiotics for preventing acute upper respiratory tract infections (Cochrane Review, CD006895.pub4)
Finding: Probiotics as a CATEGORY (not BB-12-specific) may reduce participants with at least one URTI (RR 0.76, 95% CI 0.67-0.87, P<0.001; 16 studies, 4798 participants) and may shorten mean episode duration (MD -1.22 days, 95% CI -2.12 to -0.33), but the evidence is graded low-to-moderate certainty.
View on PubMed Probiotics for respiratory tract infections in children attending day care centers - a systematic review (Laursen & Hojsak)
Finding: In the strain-specific pooled analysis, Bifidobacterium animalis subsp. lactis BB-12 showed NO effect on duration of RTIs or on absence from day care (2 studies, n=343), whereas only LGG modestly reduced RTI duration (-0.78 days).
View on PubMed Bifidobacterium animalis subsp. lactis in prevention of common infections in healthy children attending day care centers (Hojsak et al.)
Finding: BB-12 had no effect on infection prevention: 99 infections (placebo) vs 97 (BB-12), incidence rate ratio 1.0014 (P=0.992), with no difference in any respiratory, GI, duration, antibiotic-use or daycare-absence endpoint.
View on PubMed Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood (Taipale et al.)
Finding: BB-12 was associated with a borderline reduction in parent-reported respiratory tract infections (87% vs 100%; RR 0.87, 95% CI 0.76-1.00, P=0.033) but showed NO significant difference in otitis media, gastrointestinal symptoms, or fever.
View on PubMed Effect of Lactobacillus rhamnosus LGG and Bifidobacterium animalis ssp. lactis BB-12 on health-related quality of life in college students affected by upper respiratory infections (Smith et al.)
Finding: The combined LGG+BB-12 product shortened median URI duration by 2 days (P<0.001) and lowered median symptom severity by 34% (P<0.001), but BB-12's contribution cannot be isolated because it was co-administered with LGG.
View on PubMed Consumption of Bifidobacterium animalis subsp. lactis BB-12 impacts upper respiratory tract infection and the function of NK and T cells in healthy adults (Meng et al.)
Finding: Three of four BB-12 formats (yogurt-smoothie alone, BB-12 added pre-fermentation, or capsule) raised IL-2 and NK-cell cytotoxicity with fewer self-reported URTI days, but BB-12 added post-fermentation showed no effect, so benefit was formulation-dependent in a tiny crossover (n=30) measuring mainly surrogate immune markers.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
GRN 856 - Bifidobacterium animalis subsp. lactis strain BB-12; Status: FDA closure with no objections; No-Objection Letter Date: December 9, 2019; Intended Use: 'For use as an ingredient in conventional foods for use by the general population, excluding foods subject to regulation by the USDA, at levels intended to provide 5 x 10^11 CFU/serving.' Notifier: Chr. Hansen, Inc. (Milwaukee, WI). source↗
L4b EU EFSA
Cautious
Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), 'natural immune function' (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentratio… source↗
L4c UK NHS
Cautious
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. For example, there's no evidence to suggest that probiotics can help treat eczema. Probiotics are generally classed as food rather than medicine, which means they don't go through t… source↗
L5a NIH Office of Dietary Supplements
Supportive
The BB-12 Bifidobacterium animalis subsp. lactis strain is one of the most documented probiotic strains on the market and has been shown to be effective in alleviating symptoms of a low defecation frequency and infant colic, among others. The strain has been granted GRAS (generally recognized as safe) status in the United States, and the species has QPS (qualified presumption of safety) status … source↗
L5b Mayo Clinic
Supportive
Taking probiotics regularly can lower your chances of getting a cold. Probiotics appear to improve the body's immune response, which helps the body be better prepared to fight off certain infections, including the common cold. Beyond prevention, if you do catch a cold, probiotics may help reduce the severity of your symptoms and shorten how long they last. source↗
L5c Cleveland Clinic
Neutral
For example, some people take probiotics to improve their immunity during the cold and flu season. source↗
L5d Harvard Health
Cautious
Probiotics may also reduce the number of colds you'll have in a year. source↗
L5e Specialty Society (condition-mapped)
Cautious
Probiotics have been tested for their effects against upper respiratory infections (a group that includes the common cold, middle ear infections, sinusitis, and various throat infections). A 2015 evaluation of 12 studies with 3,720 total participants indicated that people taking probiotics may have fewer and shorter upper respiratory infections. However, the quality of the evidence was low beca… source↗